GERMAN PATIENT ROUNDTABLE – Cenedella.de

"Giving voice to the needs of the German Medical Marijuana/Cannabis Patient Community" / Cenedella, Patient Advocate since 1977.


Leave a comment

Grossrazzia ends legal sale of cannabis – Police stormed “Hanfbar” in Braunschweig during the opening ceremony and captured 200 units of Hanftee

Großrazzia beendet legalen Verkauf von Cannabis

A daily updated by Sadhu van Hemp

Around one million worried citizens in the greater Braunschweig area can breathe easy and let their children play on the street again. On Saturday, several dozen policemen in the anti-cannabis war were allowed to swing the repressive club in order to give the organized hemp crime a proper low blow to the benefit of the German people.

The generalstabsmäßig planned general attack took place at 6.30 pm in the city center of Brunswick, densely filled by passers-by. A large contingent of police locked the fighting area around the Friedrich-Wilhelm-Platz far and wide. In order to avoid unnecessary collateral damage in the combat operation in the anti-cannabis war, as a precaution, the public transport has been set. In the then lightning attack on the shop “Hemp Bar” the armed to the teeth people’s policemen could smoke out the resistance nest of Nutzhanfrebellen, without having to make use of the firearm.

 

police spokesman confirmed that alleged narcotics were seized and handed over to the State Office of Criminal Investigation (LKA) for analysis. Overall, it should be more than 200 so-called sales units with hemp flowers (tea). The Großrazzia had been ordered at the request of the prosecutor by a judge of the district court Braunschweig, after it had previously indicated that in the same day opened shop illicit drugs were traded.

 

The anti-drug combat mission of the police successfully carried out on Saturday is the second major battle against the operators of the “Hanfbar” in Braunschweig within a few weeks. On 3 July, the first “Hanfbar” branch in Mühlenpfordtstraße, opened in 2017, was stormed by the executive and robbed of its inventory. The apartments and the store, which is still under construction, were also turned upside down in Friedrich-Wilhelm-Strasse 47. According to the prosecutor, the search warrant was based on the suspicion that cannabis was being sold for “consumption of intoxication” in the “cannabis bar”. In the first raid three kilograms of hemp tea were confiscated. However, the LKA has not yet been able to present the test result desired by the Braunschweig prosecutor concerning the toxicity of the useful hemp flowers.

 

The owner of the “cannabis bar”, Bardia Hatefi, against whom is now being investigated on suspicion of violation of the Narcotics Act, criticized the Grossrazzia as a “farce”. The “hemp bar” would only offer food from Nutzhanf. The range includes hemp tea, hemp seeds, hemp pesto and hemp cosmetics, as well as smoothies and snacks. The THC content of the hemp flowers used would be less than 0.2 percent, is on the homepage of the “cannabis”insured. Hatefi denies having done anything illegal, since “Nutzhanf” may legally be grown and used in Germany. He accuses the public prosecutor’s office of wanting to “dry us up and fumigate us”. The seized during the raids amounts of tea would have a sales value of 50,000 euros. In addition, missing a stolen by the police from the box office five-digit sum. “You’re starting to have a sense of existential fear,” said Hatefi, who sees the actionism of the Braunschweig law enforcement agencies as “a challenge to fight” directed “against the healing plant and against all those” whom it helps “.

 


Leave a comment

Günter Weiglein wins battle in Court!

Cannabis pain patient succeeds in the appellate
court district court: proceedings for illegal cannabis cultivation set – Günter Weiglein takes medicinal hemp against chronic pain

WÜRZBURG.
Saturday, 30.06.2018 – 00:00 h
Günter Weiglein from Würzburg suffers from constant pain. As one of the first in Germany, the 53-year-old was allowed to legally buy cannabis for pain relief. Because this financially overwhelmed him, he grew hemp himself, was caught in 2016 and warned in court. He did not want to let that sit on him.

At the appeal hearing, his fight ended relatively quickly.

Weiglein’s ordeal began in 2002. In a traffic accident, he broke several bones. Since then he lives with permanent pain, especially in the left pelvic area. He could walk only 100 to 200 meters, then had to stand a minute, because it hurt so much, he described Appellate Justice Konrad Döpfner at the Würzburg district court.

Relief without side effect

The Würzburger went through all conceivable drug therapies – with significant side effects such as nausea, sweating, restless sleep. The cannabis does not eliminate the duration of pain, but alleviate it without the side effects.

When Weiglein started smoking cannabis, he claims to use six grams of medicinal hemp per day. One gram had cost 15 euros. Today, the prices would be 20 to 24 euros. Too much for the Würzburg, who currently needs eight grams per day and has to rely on the earnings of his wife of around 2600 euros.

To avoid that, Weiglein himself grew hemp. When police stopped by for an ad, they found several cannabis plants with about eight grams usable proportion and seven grams of dried hemp flowers: This Weiglein violated the narcotics law.

Mild judgment in the lower court

In the trial on 30 November 2017, the judge ruled mildly in light of Weiglein’s situation: warning instead of fine, but with punishment. The Würzburger would have to pay 300 euros, he would be caught again. This would be a new criminal case.

Weiglein appealed. It was also about the principle. He was one of three plaintiffs before the Cologne administrative court, the right to self-cultivation. However, the responsible Federal Institute for Drugs and Medical Devices issued no approval, appealed the verdict.

Before it could be decided, the Bundestag adopted in spring 2017 a law on cannabis as medicine. The health insurance companies have to actually pay for it. Weiglein’s hemp cultivation was facing this change.

In front of the Würzburg district court, Weigleins lawyer Matthias Schillo argued that it was impossible for his client to bear the high costs. He had only the choice to endure the pain or to get the necessary drug elsewhere – which was done by self-cultivation.

Although the accused fulfilled the offense under the Narcotics Act, he had not acted unlawfully. He could invoke the protected right to free development of his personality, the right to life and physical integrity. That weighs in the case heavier than the legal provisions.

Cost bears state treasury

Judge Döpfner brought two judgments of the Federal Court, which in principle state that who grows without permission hemp, makes itself punishable. Nevertheless, he stopped the proceedings with the consent of all involved. The cost of the procedure is borne by the State Treasury. For Weiglein a “bearable exit”. Every euro he would have had to pay would have made him feel guilty, he said.

Meanwhile, he and Schillo have reached with his health insurance that she paid him the medical hemp. He also found a Würzburg pharmacy, which supplies him relatively reliably despite general supply shortages. Weiglein still can not grow hemp. That he would do that, if it were not otherwise – he left no doubt on demand.

stst


Leave a comment

ABDA: The fact sheet formulation drugs with cannabis has been updated and is available for download.

ABDA:  The fact sheet formulation drugs with cannabis has been updated and is available for download.

RECIPROCAL MEDICINES WITH CANNABIS

Updated: June 21, 2018 What is cannabis?

»Cannabis is the scientific name of the genus hemp and is colloquially used for plant parts and products, in particular for marijuana (flowers of the female plant) and hashish (resin). Medicinal use of cannabis

»The data on the medicinal use of cannabis in various indications is inconsistent.1 There is good evidence for the therapeutic benefits of cannabis and cannabinoids in chronic neuropathic or cancer-related pain and spasticity due to multiple sclerosis. There are moderate evidences of efficacy against nausea and vomiting as a result of chemotherapy. In contrast, little or no evidence has been found that cannabis and cannabinoids help with chronic rheumatic pain, improve the appetite of patients with HIV and slow their weight loss, relieve symptoms of Tourette’s and anxiety disorders, psychosis or post-traumatic stress syndrome.

»On March 10, 2017, a law on the medical use of cannabis came into force. (“Act amending narcotics and other regulations”) 2> Physicians may prescribe cannabis to their patients upon prior approval by the health insurer, and pharmacies may manufacture appropriate prescription medicines. For medical use, cannabis flowers can be inhaled after being heated in special evaporators or drunk as an aqueous decoction (“tea”). > These prescription medicines containing cannabis are reimbursed by health insurances. The current Pharmaceuticals Price Regulation (AMPreisV) is applicable to the pricing of medicinal products manufactured from cannabis. Patients are required to make a co-payment of 10 percent of the drug price, but no more than 10 euros per drug.3 1 http://jama.jamanetwork.com/article.aspx?ar 2 »In 2017, pharmacies will have to pay the statutory health insurance companies around 44,000 units of cannabis prescription drugs delivered4. Statements about the number of patients or the amount are not possible. »Availability: The Federal Government had no information available in June 2018 that the delivery difficulties for cannabis flowers that occurred in the summer of 2017 persisted5. If in individual cases in a pharmacy a certain sort of cannabis flowers are not in stock, this could be the case in another pharmacy. There is also a potential for physicians to prescribe alternative cannabis-based prescription or finished medicinal products. Pharmaceutical Evaluation of Cannabis

»In total, more than 400 different ingredients have been detected in cannabis. Main ingredients are the so-called cannabinoids. Important ingredients for medical use are delta-9-tetrahydrocannabinol (Δ9-THC, also called dronabinol) and cannabidiol (CBD) in the form of largely pharmacologically inactive precursors (“THC-A” or “CBD-A”). considered. »In cannabis plants and their extracts – as with all natural products – the concentration of the various ingredients varies. There are several varieties of cannabis flowers available that contain different concentrations of the precursors of the main ingredients Δ9-THC and CBD. DAC / NRF Monographs and Formulation Regulations »The German Medicines Codex (DAC) and the New Formulation Form (NRF) are the responsibility of the DAC / NRF Commission. The publisher is the ABDA – Bundesvereinigung Deutscher Apothekerverband e. V. It appoints the independent expert DAC / NRF Commission. > DAC monographs contain information that aggregates the pharmaceutical knowledge of the active substance described. In DAC monographs u. a. Test method for identity, purity and content as well as storage and application instructions described. > NRF recipe prescriptions contain information on the preparation but also on the use of prescription drugs.

»For Dronabinol, there has been a DAC monograph since 2001 as well as the standardized NRF 4 ABDA press release dated 8 March 2018, https://tinyurl.com/y7tonsqe 5 Federal Government Response to Small Request, June 14, 2018 http: / /dip21.bundestag.de/dip21/btd/19/027/1902753.pdf 3 Formulation instructions for capsules and drops for oral use. In addition, in March 2017, the NRF formulation requirement for a solution for inhalation was pre-published.

»In 2015, a DAC monograph and an NRF prescription protocol were published for cannabidiol as the starting material and for cannabidiol solution as an oral preparation. Cannabidiol is not an anesthetic, but since 2016 de


Leave a comment

Cannabis Law – reveals legal uncertainty one year after its entry into force. A top-class group of experts debated the 22nd Eppendorfer Dialog on April 11, 2018 in Hamburg

http://www.eppendorferdialog.de/veranstaltungen/medizinischer-cannabis-zwischen-hoher-nachfrage-und-regulatorischen-huerden.html

Well meant, but from the perspective of many not concretized to the end. § 31 para. 6 SGB V, the “Law on the Amendment of Narcotic and Other Regulations” – in short: the Cannabis Law – reveals legal uncertainty one year after its entry into force. A top-class group of experts debated the 22nd Eppendorfer Dialog on April 11, 2018 in Hamburg in front of a large and dedicated participatory auditorium the experiences made so far. With increasing expectations of the patients, numerous construction sites reveal themselves: Disconcerting doctors due to missing indication formulations, high numbers of application rejections by the health insurance funds, supply bottlenecks in the medical cannabis and questions regarding the pricing. But there are also noteworthy achievements: Estimated 14.

speakers

The Eppendorfer Dialogue on Health Policy this time asked the question “Medical cannabis between high demand and regulatory hurdles: where do we stand?” Chairman Prof. Dr. med. med. Achim Jockwig had succeeded in inviting a group of experts to cover the entire range of questions surrounding the cannabis law.

Therapy benefit for patients outweighs evidence deficit

It all started with the representative of the Federal Ministry of Health, which is responsible for the realization of the law. The spokeswoman for health policy of the CDU / CSU parliamentary group Karin Maag explained the background to a legal adoption of a therapy in which the usually required evidence standards could not be applied. Maag: “There are many patients with serious illnesses, for whom there is no alternative recognized by medicine, if the standard therapy does not help.” It has been shown – according to Maag – that cannabis is a good treatment option in diseases such as multiple Sclerosis, AIDS, epilepsy or chronic pain can be. These people should be helped. Another impetus was given by the new legal situation and the critical question of self-cultivation. Politics had to act and, in March 2017, passed a law of high political significance and relevance for the everyday care routine. Since then, the use of cannabis for medical purposes is possible – but only to these. The Cannabis Law controls and controls the manufacture and distribution of medicinal hemp. All parties involved must comply with the narcotic and drug legislation. The Cannabis Law controls and controls the manufacture and distribution of medicinal hemp. All parties involved must comply with the narcotic and drug legislation. The Cannabis Law controls and controls the manufacture and distribution of medicinal hemp. All parties involved must comply with the narcotic and drug legislation.

“Once again, we make it clear that a patient does not have to endure serious side effects for many years before he can get approved for the therapeutic alternative of a cannabis drug, and we have strengthened the therapy sovereignty of the doctors. In the future, they will prescribe on the basis of their own examination that any exemption will be waived. “(Karin Maag)

Health policy has found a viable solution in their view by setting very definite standards for the supply of medicinal cannabis. Furthermore, the law is open to rework, says Maag.

Health insurance companies feel overwhelmed by the law

In addition to standardization requirements for cultivation, processing, active substance content and delivery, the standards stipulated in the law include the description of the parameters under which patients are reimbursed for a cannabis therapeutic. And here lies the crux, because the formulations are too concretely many doctors as well as the health insurance companies. This leads to uncertainty at the regulation level and substantiates a large number of the application rejections by the health insurance companies. Dr. Detlev Parow (Business Unit Product and Payroll Management at DAK-Health) describes the decision-making process at the health insurance fund, which according to the law may only refuse a pension application in justified exceptional cases. But what does exceptional case mean? “As the disease is very vague and the indications are completely open, With the exception of palliative care, we see ourselves in the situation of having to obtain nearly 100 percent of the MDK’s assessment. Due to the assessments, which also take time to annoy all beyond the defined deadlines, currently about 30 percent of the applications are rejected, “said Dr. med. Parow. Like other insurers, the DAK sees itself, to a certain extent, in the protective position of the solidary community of insured persons. Dr. Parow puts the treatment costs per patient per year at up to 30,000 euros and at the same time alludes to the lack of treatment evidence. He demands a time limit for the approval with subsequent verification. However, this statement was objected to in the discussion

“The health insurance companies are not the dark side of power when it comes to obstructions. The path from application to approval is too many pitfalls. “(Dr. Detlev Parow)

Cannabis therapy in practice: Pain patients benefit in the first place

The renowned palliative physician and Federal Cross of Merit Professor Winfried Hardinghaus, chief physician of the Clinic for Palliative Medicine Franziskus Hospital at the Charité Berlin and Chairman of the German Hospice and PalliativeVerband, emphasizes at the beginning of his presentation on the therapeutic benefits of cannabis medication that he neither the thin Evidence still the unconcrete indication description holds bad. Finally, one has the meta-analysis and the results of the CaPRis study. In addition, Prof. Hardinghaus considers the side effect potential of medicinal cannabis to be low – especially in comparison to many classic medicines. Prof. Hardinghaus describes the influence of cannabis drugs on the cannabis receptors and points out It is precisely the combination of THC and CBD that has a positive effect on chronic pain, the improvement of nausea and vomiting, as well as an increase in appetite. However, interactions with, for example, amphetamines, antihistamines, barbiturates and, in particular, psychotropic drugs and dronabinol must be taken into account at low organic side effects and low addictive potential in medical applications. As the effect of medicinal cannabis is known, Prof. Hardinghaus welcomes the fact that the legislator does not specifically specify the indications and thus does not further regulate the therapeutic use. This opens up opportunities, especially for oncological concomitant therapy. “If we get 30 percent pain improvement, that’s a lot and relevant,” said the palliative care physician. Many colleagues would shy away from the regulation because they would not be able to handle cannabis therapy. He advises him to use the offered prescription aids for doctors. Doctors in the auditorium ask why, given the high level of side effects associated with the treatment of pain, it is justifiable that these should be prescribed if medical cannabis is the alternative.

“I do not want to give up cannabis on my palliative care ward.” (Prof. Winfried Hardinghaus)

Regulatory conflicts fuel legal uncertainty in the handling of cannabis medication

He is surprised that one wonders that in Germany so far no one has researched cannabis therapy, said the medical lawyer and board member of the German Society for Palliative Medicine. Oliver Tolmein. Given the current legal situation of cannabis in our country, it is in no way surprising that there is no evidence. Which claim should you have invested in research? Dr. Tolmein explains the regulatory situation of prescribers, pharmacists, manufacturers, and patients with the entry into force of the cannabis law. This is characterized by a high degree of legal uncertainty. The conflicts are primarily related to a crisis in evidence-based medicine. In the case of the complex herbal medicine, this leads to cannabis, Regulatory restrictions and unconcrete formulations have to be carried out on the shoulders of all stakeholders. Tolmein: “To deal with this conflict, we have to ask ourselves whether we want to have evidence as the only criterion, or whether there are other criteria for patient benefit, which ultimately lead to legal certainty.” At this point, the in Auditorium present protection police and reports on the uncertainty, for example, in traffic. The requirement: Medicinal cannabis regulations should be treated in the traffic regulations as a normal drug. So far, people who take medical cannabis regularly, the driving license must be withdrawn. “To cope with this conflict, we need to ask ourselves if we want evidence as the only criterion, or if there are other criteria for patient benefit that ultimately lead to legal certainty.” This is where the audience present at the auditorium announces Protective police to word and reports on the uncertainty, for example, in traffic. The requirement: Medicinal cannabis regulations should be treated in the traffic regulations as a normal drug. So far, people who take medical cannabis regularly, the driving license must be withdrawn. “To cope with this conflict, we need to ask ourselves if we want evidence as the only criterion, or if there are other criteria for patient benefit that ultimately lead to legal certainty.” This is where the audience present at the auditorium announces Protective police to word and reports on the uncertainty, for example, in traffic. The requirement: Medicinal cannabis regulations should be treated in the traffic regulations as a normal drug. So far, people who take medical cannabis regularly, the driving license must be withdrawn. “At this point, the protection police present in the auditorium speaks up and reports on the uncertainty, for example in traffic. The requirement: Medicinal cannabis regulations should be treated in the traffic regulations as a normal drug. So far, people who take medical cannabis regularly, the driving license must be withdrawn. “At this point, the protection police present in the auditorium speaks up and reports on the uncertainty, for example in traffic. The requirement: Medicinal cannabis regulations should be treated in the traffic regulations as a normal drug. So far, people who take medical cannabis regularly, the driving license must be withdrawn.

“It has been contested by the patients up to the Federal Administrative Court that today we can talk about the regulation of cannabis.” (Dr. Oliver Tolmein)

It has become clear that the cannabis law has set in motion medical advances accompanied by a great wave of questions and uncertainties. There is still much to be done for medical cannabis therapy to do what it can do: to relieve people of their suffering.

Presentation of the speakers

Dr. med. Detlev Parow on cannabis as a medicine

Prof. Dr. med. Winfried Hardinghaus on cannabis as a therapy

Dr. Oliver Tolmein on the subject of cannabis as medicine

Flyer to the event


Leave a comment

‘A puff a day’ can keep Alzheimer’s away, says cannabis researcher at The Ohio State University.

https://420intel.com/articles/2018/05/29/puff-day-can-keep-alzheimers-away-says-cannabis-researcher-0?utm_source=420+Intel+-+Marijuana+Industry+News&utm_campaign=28e2059f64-420+Intel&utm_medium=email&utm_term=0_3210cbef52-28e2059f64-278148489

Cannabis may be an effective treatment for Alzheimer’s disease, says Dr. Gary Wenk of Ohio State University. That’s because Alzheimer’s is linked to brain inflammation and cannabis has known anti-inflammatory properties, writes Calvin Hughes.

Wenk’s research has found that early detection of brain inflammation can determine whether someone will develop Alzheimer’s disease nearly 40 years before it sets in. He says that while brain inflammation happens naturally as people age, it can also be induced by injury or trauma.

So athletes and anyone else who has suffered a blow to the head might want to look into medical marijuana now to offset the lingering effects of their injuries later.

Even at very low dosages – as little as “a puff a day” – brain inflammation was noticeably reduced, Dr. Wenk found after experimenting on lab rats.

Those results have inspired Wenk to tell his students, “that if their patients were in a car accident and had a severe head injury, the first thing they should tell their patient to do is start smoking marijuana heavily for the next few weeks because it would protect the brain.”